09966.HK
Alphamab Oncology
HKSE · Healthcare · Biotechnology · CN
HKD 6.49
−0.92%Oct 29, 2026, 01:44 UTC
Alphamab Oncology announced that the first patient had been dosed in its Phase III JSKN033 monotherapy study for recurrent or metastatic cervical cancer.
Source:Oct 26, 2026, 04:22 UTC
Alphamab Oncology announced clinical study results: as of June 20, the China Phase I/II JSKN033-102 study had enrolled 64 patients with cervical cancer whose disease had failed standard treatment, who received JSKN033 monotherapy; the results were presented as a rapid oral presentation at the 2026 ESMO Congress.
Source:Aug 30, 2026, 16:45 UTC
Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.
Source:Aug 27, 2026, 18:02 UTC
Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.
Source:Aug 18, 2026, 13:04 UTC
China's National Medical Products Administration accepted the new drug application for KN026 combined with HB1801 for first-line treatment of advanced breast cancer, developed by CSPC Group's subsidiary Jinmantebio and Alphamab Oncology, and granted priority review.
Source:Aug 4, 2026, 10:07 UTC
Alphamab Oncology and CSPC Pharmaceutical Group subsidiary Jinmantebio's new drug application for anlotinib combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer has been accepted by China's National Medical Products Administration and included in priority review.
Source:Aug 4, 2026, 00:45 UTC
Jiangsu Alphamab (subsidiary of Alphamab Oncology) granted Pathos AI exclusive rights to develop, manufacture, and commercialize JSKN016 outside mainland China, Hong Kong, Macau, and Taiwan under a licensing agreement.
Aug 3, 2026, 14:44 UTC
Alphamab Oncology's JSKN033, a high-concentration subcutaneous compound formulation of a bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, was approved by the Center for Drug Evaluation of China's National Medical Products Administration to conduct a Phase III clinical study as monotherapy for recurrent or metastatic cervical cancer that has failed platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment.
Source: